Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Sep 2025 value amounting to $1.3 million.

  • Phathom Pharmaceuticals' Gains from Sales and Divestitures rose 51.43% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 51.43%. This contributed to the annual value of $965,881 for FY2024, which is 4.36% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Gains from Sales and Divestitures stood at $1.3 million, which was up 36.34% from $965,245 recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Gains from Sales and Divestitures registered a high of $1.3 million during Q3 2025, and its lowest value of $102,453 during Q4 2022.
  • For the 3-year period, Phathom Pharmaceuticals' Gains from Sales and Divestitures averaged around $675,385, with its median value being $508,568 (2025).
  • In the last 5 years, Phathom Pharmaceuticals' Gains from Sales and Divestitures spiked by 885.77% in 2023 and then dropped by 4.36% in 2024.
  • Phathom Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $102,453 in 2022, then spiked by 885.77% to $1.0 million in 2023, then decreased by 4.36% to $965,881 in 2024, then soared by 51.43% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $965,245 for Q2 2025, and $508,568 during Q1 2025.